This study is in progress, not accepting new patients
Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis
Summary
- Eligibility
- for people ages 18-65 (full criteria)
- Location
- at UCLA
- Dates
- study startedcompletion around
Description
Summary
Official Title
Details
Keywords
Eligibility
Locations
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Immunic AG
- ID
- NCT05054140
- Phase
- Phase 2 Multiple Sclerosis Research Study
- Study Type
- Interventional
- Participants
- Expecting 450 study participants
- Last Updated